© 2024 HSP News Service, L.L.C.
Patients with prostate cancer who undergo active monitoring may experience the same 15-year survival rates as those who undergo radiotherapy or surgery, according to new findings published by Hamdy et al in The New England Journal of Medicine and simultaneously presented at the 2023 European...
Researchers have found that a novel technique used during prostate cancer surgery may reduce the risk of postoperative lymphocele by 50%, according to new findings presented by Neuberger et al at the 2023 European Association of Urology Annual Congress (Abstract A0656). The technique—involving the...
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
A trial conducted at the University Hospital Bonn, Germany, has been testing the benefit of PSMA-PET/CT (prostate-specific membrane antigen–positron-emission tomography/computed tomography) to help target where to take biopsy samples, potentially improving the diagnosis of prostate cancer by giving ...
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
“There are misconceptions about prostate cancer screening,” Karen Knudsen, MBA, PhD, said in an interview with The ASCO Post about newly published cancer statistics, including an increased incidence of prostate cancer, particularly advanced-stage disease. Dr. Knudsen is Chief Executive Officer of...
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
In a study reported in the Journal of Clinical Oncology, Derya Tilki, MD, and colleagues identified a prostate-specific antigen (PSA) level cutpoint, above which initiation of salvage radiation therapy after radical prostatectomy was associated with an increased risk of all-cause mortality in...
Researchers have identified nine new genetic variants that may increase the risk of developing prostate cancer in Black patients, according to a novel study published by Chen et al in European Urology. The investigators also found that genetic differences may help determine which patients are most...
Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate, and urothelial cancer trials to more accurately reflect the real-world population and reducing exclusion criteria. (Abstract 662, 612, 34, 453)
In an analysis from the phase III ARASENS trial reported in the Journal of Clinical Oncology, Maha Hussain, MD, FACP, FASCO, and colleagues found that the addition of darolutamide to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival in subgroups of patients...
Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses study results showing that, the anti-PSMA (prostate-specific membrane antigen) monoclonal antibody J591 with ketoconazole and hydrocortisone, when radiolabeled with lutetium-177, leads to improved 18-month metastasis-free survival vs radiolabeling with indium-111 in patients with nonmetastatic (M0) castration-resistant prostate cancer. This supports the development of anti-PSMA radioimmunotherapy, although the optimal radionuclide and targeting agent are unknown. (Abstract LBA21).
Alan H. Bryce, MD, of the Mayo Clinic, discusses the final results of the primary endpoint of rPFS and interim results on overall survival among patients with chemotherapy-naive metastatic castration-resistant prostate cancer. The data showed that rucaparib improved radiographic progression-free survival compared with either docetaxel or abiraterone and enzalutamide in disease with BRCA1/2 alterations. (Abstract 18).
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses phase III findings from the KEYNOTE-921 study, which was designed to assess the combination of pembrolizumab and docetaxel in the treatment of patients with metastatic castration-resistant prostate cancer. They had not received chemotherapy, but their disease progressed on the next-generation hormonal agent, or they could not tolerate the agent. (Abstract 19).
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses results from the FORMULA-509 study, which compared postoperative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide, after radical prostatectomy. The study suggested that adding AAP and apalutamide to salvage radiotherapy, plus 6 months of androgen-deprivation therapy, may improve outcomes, particularly in the subgroup of patients with a prostate-specific antigen level higher than 0.5 ng/mL. (Abstract 303).
Investigators have estimated the environmental impacts of prostate magnetic resonance imaging (MRI) scans and prostate biopsies, according to a new study published by Michael S. Leapman, MD, MHS, and colleagues in European Urology. The findings suggest that more carefully selecting patients for...
Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discusses phase III results from the TALAPRO-2 study, which suggested an improvement in radiographic progression-free survival with the combination of talazoparib and enzalutamide over standard-of-care enzalutamide alone as first-line treatment in patients with metastatic castration-resistant prostate cancer. The improvement was seen regardless of homologous recombination repair gene mutations. The combination regimen delayed the time to chemotherapy and worsening in global health status and quality of life. (Abstract LBA17).
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the entire population of patients with metastatic...
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free survival vs the current standard of care for patients with metastatic...
Patients with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of disease progression and a 53% lower risk of recurrence compared with those who had the lowest amounts of plants in their diets. The diet assessments were based on...
In a study reported in JAMA Oncology, Mariados et al found that use of a hyaluronic acid rectal spacer reduced radiation exposure of the rectum—and reduced the incidence of grade ≥ 2 gastrointestinal (GI) toxicity—in patients receiving hypofractionated radiation therapy for prostate cancer. Study...
A decline in prostate-specific antigen (PSA) levels following treatment with the androgen receptor inhibitor enzalutamide may effectively predict improved survival rates among patients with nonmetastatic castration-resistant prostate cancer, according to a post hoc analysis of data from the PROSPER ...
In a European phase II trial (Swiss Group for Clinical Cancer Research [SAKK] 08/16) reported in the Journal of Clinical Oncology, Silke Gillessen, MD, and colleagues found that darolutamide maintenance improved progression-free survival vs placebo in patients with metastatic castration-resistant...
In a study reported in JAMA Surgery, Zhang et al found that focal and extended irreversible electroporation (IRE) produced similar results in the ablation of low- or intermediate-risk prostate cancer. Study Details In the study, 106 patients from five European centers were randomly assigned between ...
Oxidative stress is a key factor in the development of many diseases including cancer. Antioxidants prevent cellular damage by neutralizing free radicals and are being investigated as potential therapeutic strategies against cancer. In this installment of The ASCO Post’s Integrative Oncology...
In the single-center phase III MIRAGE trial reported in JAMA Oncology, Amar U. Kishan, MD, and colleagues found that use of margin reduction with magnetic resonance imaging (MRI)-guided stereotactic body radiotherapy (SBRT) resulted in significantly reduced acute genitourinary (GU) and...
The American Cancer Society has released its Cancer Statistics 2023 report, which showed that overall cancer mortality has dropped by 33% since 1991, averting an estimated 3.8 million cancer deaths. Data in the report, which was published by Siegel et al in CA: A Cancer Journal for Clinicians, also ...
For patients with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggest findings from a preliminary clinical trial published by Schweizer et al in The Journal of Urology. "In our...
Investigators recently examined prostate cancer screening among primary care providers and found that screening tests were frequently used—even when they provide little value to patients, according to a new study published by Gillette et al in the Journal of the American Board of Family Medicine....
New findings revealed that the highest mortality rates for prostate cancer among White male patients were found in the Western United States—including California—despite low incidence rates, according to a new study published by Schafer et al in European Urology. However, when compared with White...
In a study reported in the Journal of Clinical Oncology, Nyberg et al developed the risk model CanRisk-Prostate for predicting the development of prostate cancer based on age, detailed cancer family history, moderate- to high-risk pathogenic variants, and a polygenic score for common low-risk...
In a Swedish study (GÖTEBORG-2) reported in The New England Journal of Medicine, Hugosson et al found that magnetic resonance imaging (MRI)-targeted prostate biopsy was associated with a lower risk of overdiagnosis of clinically insignificant prostate cancer compared with MRI-targeted and...
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate cancer on androgen-deprivation therapy. These findings were presented at the 2022 American Society for...
On December 5, Novartis announced the pivotal phase III PSMAfore study of lutetium (Lu-177) vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. The therapy demonstrated a statistically significant and clinically meaningful...
More than 1.4 million patients were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world. In the final days of the Movember campaign, which every year in November aims to raise awareness of...
In a phase II trial (SALV-ENZA) reported in the Journal of Clinical Oncology, Phuoc T. Tran, MD, PhD, and colleagues found that the addition of enzalutamide to salvage radiotherapy improved freedom from prostate-specific antigen (PSA) progression in patients with biochemically recurrent prostate...
In a Canadian phase III trial (MITNEC-A1) reported in The Lancet Oncology, Bénard et al found that fluorine-18–sodium fluoride (F-18–NaF) positron-emission tomography-computed tomography (PET-CT) was more accurate in detecting skeletal metastases vs technetium-99m–methylene diphosphonate...
An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...
On March 23, 2022, the radioligand therapeutic agent lutetium Lu-177 vipivotide tetraxetan was approved for treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor ...
In a pooled analysis (SANDSTORM) reported in the Journal of Clinical Oncology, Ma et al found that concurrent/adjuvant short-term androgen-deprivation therapy (ADT) with prostate-only radiotherapy (PORT) was associated with better outcomes in multiple measures vs neoadjuvant/concurrent ADT with...
In a prespecified analysis from the Australian phase II TheraP trial reported in The Lancet Oncology, Buteau et al found that higher gallium-68–labeled PSMA-11 positron-emission tomography (PSMA-PET) mean standardized uptake values (SUVmean) were associated with a greater likelihood of...
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
In a retrospective cohort study reported in JAMA Oncology, Bryant et al found that prostate-specific antigen (PSA) screening rates at Veterans Health Administration (VHA) facilities declined between 2005 and 2019—and that diagnoses of metastatic prostate cancer increased over the same time period....
As reported in the Journal of Clinical Oncology by Kim et al, the phase II National Cancer Institute 9984 trial has shown prolonged radiographic progression-free survival with the addition of cediranib to olaparib in patients with metastatic castration-resistant prostate cancer. Study Details In...
In the European phase IIIb PRESIDE trial reported in The Lancet Oncology, Merseburger et al found that treatment with docetaxel and continuing enzalutamide vs placebo improved progression-free survival in patients with metastatic castration-resistant prostate cancer who had disease progression on...
NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multimodal artificial intelligence models (MMAI) that could outperform the National Comprehensive Cancer...